click below
click below
Normal Size Small Size show me how
Therapeutic antibodi
FA Immuno
| Question | Answer |
|---|---|
| CD52 | Alemtuzumab |
| CLL | Alemtuzumab |
| colorectal Ca, RCC | Bavacizumab |
| Stage IV colorectal Ca, head and neck Ca | Cetuximab |
| B cell non-Hodgkin lymphoma, CLL, RA, ITP | Rituximab |
| Breast Ca | Trastuzumab |
| VEGF | Ranibizumab, bevacizumab |
| EGFR | Cetuximab |
| CD20 | Rituximab |
| Her2/neu | Trastuzumab |
| Soluble TNF alpha | Adalimumab, infliximab |
| IBD, RA, Ankylosing spondylitis, psoriasis | Adalimumab, infliximab |
| decoy TNF alpha receptor | Etanercept |
| Complement protein C5 | Eculizumab |
| PNH | Eculizumab |
| alpha 4 integrin | Natalizumab |
| MS, Crohn disease | Natalizumab |
| Platelet glycoprotein IIb/IIIa | Abciximab |
| antiplatelet agent for prevention of ischemic complications in patients undergoing percutaneous coronary intervention | Abciximab |
| RANKL | Denosumab |
| osteoporosis | Denosumab |
| inhibits osteoclast maturation (mimics osteoprotegerin) | Denosumab |
| Antidote for digoxin toxicity | Digoxin immune Fab |
| IgE | Omalizumab |
| Allergic asthma, prevents IgE binding to FcERI | Omalizumab |
| RSV F Protein | Palivizumab |
| RSV prophylaxis for high risk infants | Palivizumab |
| neovascular age related macular degeneration | Ranibizumab, bevacizumab |